Diagnostic performance of the biomarkers HE4 and CA125 in type i and type II epithelial ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 52-58

  Kristjansdottir, Björg ^a   Levan, Kristina ^a   Partheen, Karolina ^a   Sundfeldt, Karin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

CA125; Diagnostic biomarkers; Epithelial ovarian cancer; HE4; Type I and type II EOC

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INTERNATIONAL CLASSIFICATION OF DISEASES; INTERNATIONAL FEDERATION OF OBSTETRICIANS AND GYNECOLOGIST; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84885295889     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.094     Document Type: Article

References (28)

1. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012;23(Suppl. 10): x111-7.
2. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31: 161-9.
3. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164: 1511-8.
4. Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ. The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol 2011;30: 4-11.
5. Badgwell D, Bast Jr RC. Early detection of ovarian cancer. Dis Markers 2007;23: 397-410.
6. Singer G, Kurman RJ, ChangHW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160: 1223-8.
7. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34: 433-43.
8. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011;42: 918-31.
9. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474: 609-15.
10. Guth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G. Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 2007;110: 1272-80.
11. Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol 2011;22: 244-52.
12. Moore RG, Brown AK, Miller MC, Skates S, AllardWJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108: 402-8.
13. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309: 883-7.
14. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63: 3695-700.
15. Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion andmotility. BiochemBiophys Res Commun 2012;419: 274-80.
16. Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep 2011;3:22.
17. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009;6:e1000114.
18. Lu D, Kuhn E, Bristow RE, Giuntoli II RL, Kjaer SK, Shih IeM, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011;122: 560-6.
19. Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer 2011;105: 1818-24.
20. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112: 40-6.
21. Yemelyanova AV, Cosin JA, BidusMA, Boice CR, Seidman JD. Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer 2008;18: 465-9.
22. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104: 863-70.
23. KarlsenMA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarianmalignancy algorithm (ROMA) and risk ofmalignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127: 379-83.
24. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008;3: e2633.
25. Drapkin R, von Horsten HH, Lin Y,Mok SC, CrumCP,WelchWR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65: 2162-9.
26. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010;19: 859-68.
27. van Nagell Jr JR, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109: 1887-96.
28. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010;116: 1462-8.